Indefinite Delivery Contract 75D30122D14069
Award Date
7/1/22
Last Date to Order
6/30/23
Federal Agency
CDC Pittsburgh
Awardee
Dynavax Technologies Corporation
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract worth up to $58,450,000 to Dynavax Technologies Corporation (Dynavax) for the purchase of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and is not set-aside.
The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The $99,015,000 multiple-award contract has a period of performance from July 1, 2024 to June 30, 2025. The contract does not utilize any set-asides.
The solicitation seeks the purchase of vaccines for Hepatitis A, Hepatitis B, Hepatitis...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) has awarded a 5-year, $154.3 million indefinite delivery, indefinite quantity (IDIQ) contract to Glaxosmithkline, LLC for the provision of various adult vaccines. The contract period of performance is from July 1, 2024 to June 30, 2025, with vaccines ordered via the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process.
The required vaccine types include...
Dynavax Technologies Corporation was awarded a single-award Indefinite Delivery Contract by the Centers for Disease Control and Prevention. The contract has a potential value of $27.4M to deliver adult vaccines in support of the CDC's national immunization programs. No set-asides were specified. Performance will take place through June 2021.
Under this contract, Dynavax will provide a range of pharmaceutical products and services. This includes delivering adult vaccines to the CDC to support...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor.
The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts hold a potential value of $102.6 million and require the awarded vendors to provide 13 vaccines to support immunization programs administered by state and local health authorities pursuant to Section 317(j) of the Public Health Service Act. Vaccines include hepatitis A and B, pneumococcal, tetanus/diphtheria, herpes...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Dynavax Technologies Corporation, a biopharmaceutical company focused on immune system responses. The contract, valued at $28,105,875.00, covers the provision of adult vaccines to support the CDC's national immunization programs. As a multiple-award IDC, the contract allows for the continued issuance of task orders to Dynavax over the performance period, which runs through June 30,...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts to Pfizer Inc. for the delivery of various adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $62.2 million.
Through these contracts, Pfizer will provide 12 standard adult vaccines to the CDC including hepatitis A & B, pneumococcal, tetanus/diphtheria, herpes zoster, Tdap, MMR,...